CAR T-cell therapy for B-cell cancer in children and young adults
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new CAR T-cell therapy made locally for children and young adults with B-cell cancers that have come back or not responded to other treatments. The therapy uses your own immune cells, modified to find and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 45 years old.
- You must have a B-cell cancer (like lymphoma or leukemia) that is CD19-positive and has come back or not responded to standard treatments.
- You must have tried all standard treatments that could possibly cure you, or you can't have them.
- You must have visible signs of cancer (like a tumor or cancer cells in the bone marrow).
- You need to be in fairly good health overall (able to do daily activities).
- If you could become pregnant, you must agree to use effective birth control for a year after treatment and not breastfeed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
This trial tests whether giving you a special kind of immune cell, called a CAR T cell, can help fight your B-cell leukemia or lymphoma that has come back or not gone away with standard treatments. The cells are made from your own blood and designed to attack the cancer cells that carry a marker called CD19.
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
This trial tests a new CAR T cell treatment for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The goal is to see if this therapy is safe and can help control the cancer so a stem cell transplant may be possible.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.